DCT

1:26-cv-03559

Abraxis Bioscience LLC v. DR Reddy's Laboratories Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-03559, D.N.J., 04/02/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendants' systematic and continuous contacts with the state, their business of manufacturing, marketing, and selling generic drug products in the district, and the fact that the district will be a destination for the accused generic drug product.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the cancer drug Abraxane® constitutes an act of patent infringement under the Hatch-Waxman Act.
  • Technical Context: The technology concerns methods of treating various cancers using nanoparticle albumin-bound paclitaxel, a formulation designed to improve the delivery and reduce the side effects of the widely-used chemotherapy agent paclitaxel.
  • Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' filing of ANDA No. 214724 with a Paragraph IV certification, asserting that their proposed generic product does not infringe Plaintiff's patents or that the patents are invalid. The patents-in-suit are listed in the FDA's Orange Book for the brand-name drug Abraxane®. The complaint notes prior litigation in the district involving the same plaintiff and "certain of the same patents" against other generic drug manufacturers.

Case Timeline

Date Event
2005-02-18 '375 Patent and '318 Patent Priority Date
2011-01-14 '409 Patent Priority Date
2011-10-11 '375 Patent Issued
2013-01-11 '046 Patent Priority Date
2016-07-19 '318 Patent Issued
2016-12-06 '046 Patent Issued
2017-03-21 '409 Patent Issued
2026-02-18 (no earlier than) DRL's Paragraph IV Notice Letter Sent
2026-04-02 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,034,375 - Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy

  • Patent Identification: U.S. Patent No. 8,034,375 ("Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy"), issued October 11, 2011 Compl. ¶5

The Invention Explained

  • Problem Addressed: The patent's background section describes the significant shortcomings of conventional cancer therapies, including severe side effects from chemotherapy, the development of multi-drug resistance (MDR), and the narrow therapeutic window of many anticancer agents '375 Patent, col. 1:24-37 '375 Patent, col. 2:36-50
  • The Patented Solution: The invention proposes combination therapies that use a taxane, such as paclitaxel, formulated into nanoparticles with a carrier protein like albumin (e.g., Abraxane®) '375 Patent, abstract This nanoparticle formulation is described as having superior anti-tumor activity and reduced toxicity, which enables its effective use in combination with other chemotherapeutic agents or in "metronomic" (frequent, low-dose) dosing regimens to overcome the problems of toxicity and drug resistance '375 Patent, col. 10:32-44
  • Technical Importance: The invention provides a platform for improving the therapeutic index of paclitaxel, allowing for novel combination therapies and dosing strategies that were previously not feasible due to the toxicity of solvent-based formulations.

Key Claims at a Glance

  • The complaint does not identify any specific claims asserted, alleging infringement of "one or more claims" of the '375 Patent Compl. ¶30 Independent claim 1 is representative of the patent's core combination therapy concept.
  • Independent Claim 1 of the '375 Patent recites:
    • A method of treating a proliferative disease in an individual comprising administering to the individual:
    • a) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin; and
    • b) an effective amount of a platinum-based agent, wherein the composition comprising nanoparticles and the platinum-based agent are administered sequentially.
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 9,393,318 - Methods of Treating Cancer

  • Patent Identification: U.S. Patent No. 9,393,318 ("Methods of Treating Cancer"), issued July 19, 2016 Compl. ¶6

The Invention Explained

  • Problem Addressed: Similar to the '375 Patent, the background of the '318 patent describes the limitations of existing cancer treatments, including poor efficacy and significant toxicity, particularly for non-small-cell lung cancer (NSCLC) '318 Patent, col. 1:26-col. 2:67
  • The Patented Solution: The invention provides a specific method for treating NSCLC using a combination of a paclitaxel/albumin nanoparticle composition and the platinum-based agent carboplatin '318 Patent, abstract It details a specific, clinically evaluated dosing regimen: administering the paclitaxel nanoparticles at about 100 mg/m² weekly and carboplatin at a dose of about AUC=6 once every three weeks '318 Patent, col. 5:1-12
  • Technical Importance: The invention provides a defined, clinically tested dosing schedule for a combination therapy, moving beyond a general concept to a specific, practical application for treating NSCLC.

Key Claims at a Glance

  • The complaint does not identify any specific claims asserted, alleging infringement of "one or more claims" of the '318 Patent Compl. ¶39 Independent claim 1 is representative of the patent's specific method.
  • Independent Claim 1 of the '318 Patent recites:
    • A method of treating non-small cell lung cancer (NSCLC) in a human individual comprising administering to the individual:
    • (a) nanoparticles comprising paclitaxel and an albumin; and
    • (b) carboplatin,
    • wherein the nanoparticles and the carboplatin are administered intravenously,
    • wherein the paclitaxel is administered at a dose of about 100 mg/m² weekly, and
    • wherein the carboplatin is administered at a dose of about AUC=6 once every three weeks.
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 9,511,046 - Methods of Treating Pancreatic Cancer

  • Patent Identification: U.S. Patent No. 9,511,046 ("Methods of Treating Pancreatic Cancer"), issued December 6, 2016 Compl. ¶7
  • Technology Synopsis: The patent addresses the challenges of treating pancreatic cancer and provides a method for treating metastatic adenocarcinoma of the pancreas. The solution involves administering a combination of a paclitaxel/albumin nanoparticle composition and gemcitabine according to a specific dosing schedule '046 Patent, abstract
  • Asserted Claims: The complaint alleges infringement of "one or more claims" of the '046 Patent Compl. ¶48 The patent contains independent claims 1 and 19.
  • Accused Features: The accused instrumentality is alleged to infringe because its proposed labeling will instruct physicians to use the generic product to treat metastatic adenocarcinoma of the pancreas in combination with gemcitabine, which is an FDA-approved use for Abraxane® Compl. ¶9 Compl. ¶11

U.S. Patent No. 9,597,409 - Methods of Treating Cancer

  • Patent Identification: U.S. Patent No. 9,597,409 ("Methods of Treating Cancer"), issued March 21, 2017 Compl. ¶8
  • Technology Synopsis: The patent addresses the challenges of treating cancer and provides methods for treating prostate cancer. The solution involves administering a composition of nanoparticles comprising docetaxel and an albumin in combination with a steroid '409 Patent, abstract
  • Asserted Claims: The complaint alleges infringement of "one or more claims" of the '409 Patent Compl. ¶57 The patent contains independent claims 1 and 16.
  • Accused Features: The complaint alleges infringement by DRL's ANDA Product, which is a generic version of paclitaxel-based Abraxane® Compl. ¶1 The claims of the '409 patent, however, are directed to methods using docetaxel, a different taxane drug.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendants' proposed generic version of Abraxane® (paclitaxel protein-bound particles for injectable suspension), which is the subject of Abbreviated New Drug Application (ANDA) No. 214724 ("DRL's ANDA") Compl. ¶1

Functionality and Market Context

The complaint alleges that DRL's ANDA Product is a generic drug intended to be a substitute for Plaintiff's FDA-approved cancer medicine, Abraxane® Compl. ¶1 Compl. ¶9 The act of infringement alleged is the submission of the ANDA to the FDA seeking approval to market this generic drug prior to the expiration of the patents-in-suit, an act defined as infringement under 35 U.S.C. § 271(e)(2) Compl. ¶30; Compl. ¶39; Compl. ¶48; Compl. ¶57 The complaint further alleges that the labeling for the proposed generic product will instruct and encourage its administration for FDA-approved indications, such as metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer, using methods claimed in the patents-in-suit Compl. ¶9 Compl. ¶11

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide claim charts or detailed infringement allegations beyond boilerplate assertions. The following charts summarize the infringement theory as inferred from the complaint's general allegations in the context of an ANDA litigation.

'375 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating a proliferative disease in an individual DRL's proposed label for its ANDA product will instruct its use for the treatment of cancer, a proliferative disease. ¶9; ¶11 col. 1:16-18
comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin; DRL's ANDA Product is a generic version of Abraxane®, which is a composition of nanoparticles comprising paclitaxel and albumin. ¶1 col. 7:49-54
and b) an effective amount of a platinum-based agent, The proposed label will instruct for use in combination with carboplatin, a platinum-based agent, for the treatment of NSCLC. ¶9 col. 15:33-36
wherein the composition comprising nanoparticles and the platinum-based agent are administered sequentially. The proposed label will instruct users to administer the ANDA product and carboplatin sequentially. ¶11 col. 7:25-29

'318 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating non-small cell lung cancer (NSCLC) in a human individual DRL's proposed label will instruct its use for the treatment of NSCLC. ¶9; ¶11 col. 12:1-3
comprising administering to the individual: (a) nanoparticles comprising paclitaxel and an albumin; and (b) carboplatin, DRL's ANDA product is a generic of paclitaxel/albumin nanoparticles, and the proposed label will instruct for its use with carboplatin. ¶1; ¶9 col. 5:1-5
wherein the nanoparticles and the carboplatin are administered intravenously, The proposed label will instruct for intravenous administration of both DRL's ANDA product and carboplatin. ¶1; ¶11 col. 5:6-7
wherein the paclitaxel is administered at a dose of about 100 mg/m² weekly, The proposed label will instruct a dosing regimen of paclitaxel at about 100 mg/m² weekly. ¶11 col. 5:8-10
and wherein the carboplatin is administered at a dose of about AUC=6 once every three weeks. The proposed label will instruct a dosing regimen of carboplatin at about AUC=6 once every three weeks. ¶11 col. 5:10-12

Identified Points of Contention

  • Scope Questions: A primary question for the '409 Patent is one of literal scope: does a claim limitation requiring "docetaxel" read on an accused product containing only "paclitaxel"? These are distinct chemical compounds, which may present a significant barrier to proving literal infringement. For the '318 Patent, a central question will be the interpretation of the term "about" as it applies to the claimed doses. The court will need to determine the permissible range of deviation from "100 mg/m²" and "AUC=6".
  • Technical Questions: In an ANDA case, the key technical question is not how the drug works, but what the proposed label instructs. The dispute will center on whether the language in DRL's proposed label for its ANDA product directs or encourages physicians to perform all steps of the asserted method claims, thereby meeting the legal standard for inducement of infringement.

V. Key Claim Terms for Construction

'375 and '318 Patents

  • The Term: "nanoparticles comprising paclitaxel and an albumin"
  • Context and Importance: This term defines the drug composition itself. Its construction is critical because Defendants may argue that their generic formulation, while bioequivalent to Abraxane®, does not meet the specific structural or compositional properties of the "nanoparticles" as defined and claimed in the patents. Practitioners may focus on this term to dispute infringement by arguing their product falls outside the patent's definition, for example, based on particle size, albumin-to-drug ratio, or the nature of the "coating."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification of the '375 Patent describes preparing nanoparticles using various high-shear methods and notes that the weight ratio of albumin to paclitaxel can be about 18:1 or less, suggesting a wide range of possible formulations could be covered '375 Patent, col. 50:1-7 '375 Patent, col. 49:50-51
    • Evidence for a Narrower Interpretation: The specifications of both patents repeatedly identify Abraxane® as the exemplary embodiment, describing its specific properties, such as being "substantially free of surfactant" and having a mean particle size of "about 130 nanometers" '375 Patent, col. 50:30-38 '318 Patent, col. 50:1-9 This focus on a specific commercial product could be used to argue for a narrower construction limited to compositions with these particular features.

'318 Patent

  • The Term: "about 100 mg/m²" and "about AUC=6"
  • Context and Importance: These terms define the specific doses of the claimed method. The infringement analysis will turn on whether the dosing instructions in the defendant's proposed product label fall within the scope of "about" these values. Practitioners may focus on this term because if "about" is construed narrowly, even minor differences in recommended dosing on a generic label could potentially avoid infringement.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The '318 patent's specification discloses various dosing regimens and describes dose adjustments for toxicity, which suggests that the invention is not strictly limited to the exact numerical values stated in the claim and that "about" should encompass a range of clinically appropriate doses '318 Patent, col. 58:21-31
    • Evidence for a Narrower Interpretation: The patent's examples and clinical trial data are tied to specific doses, such as the 100 mg/m² weekly regimen for paclitaxel '318 Patent, col. 53, Example 1 A party could argue that the term "about" should be limited to a narrow range around this tested value, as significant deviation would represent a different, untested method.

VI. Other Allegations

Indirect Infringement

The complaint alleges induced infringement for all four patents-in-suit. The factual basis for this allegation is that the defendants' proposed product labeling will instruct and encourage physicians and other healthcare professionals to administer the generic drug in accordance with the methods claimed in the patents Compl. ¶11 Compl. ¶33 Compl. ¶42 Compl. ¶51 Compl. ¶60 This is the central infringement theory in this ANDA case. The complaint also alleges contributory infringement, stating the product is especially adapted for an infringing use with no substantial non-infringing use Compl. ¶34 Compl. ¶43 Compl. ¶52 Compl. ¶61

Willful Infringement

The complaint does not use the term "willful infringement." However, it does allege that the case is "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶37 Compl. ¶46 Compl. ¶55 Compl. ¶64 The basis for this allegation is Defendants' filing of an ANDA with a Paragraph IV certification, which demonstrates knowledge of the patents-in-suit.

VII. Analyst's Conclusion: Key Questions for the Case

  • Definitional Mismatch: A central issue for the '409 patent will be one of non-infringement based on claim language. Can claims explicitly requiring the administration of "docetaxel" be infringed by a product that contains only "paclitaxel," a distinct chemical entity?
  • Scope of "About": For the '318 patent and others with specific dosing limitations, a key question will be one of claim construction: how broadly will the court interpret the term "about" when defining the claimed dosages? This will determine whether the dosing instructions on the defendants' proposed product label fall within the scope of the claims.
  • Inducement via Label: A core evidentiary question will be whether the language in the defendants' proposed drug label rises to the level of actively encouraging or instructing infringement, as required to prove the specific intent for inducement, or if it merely makes infringing uses possible without active encouragement.
Loading Complaint